Details of the Drug

General Information of Drug (ID: DM0659E)

• Drug Name: Cannabidiol
• Synonyms: cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; UNII-19GBJ60SN5; (-)-trans-2-p-Mentha-1,8-dien-3-yl-5-pentylresorcinol; delta1(2)-trans-Cannabidiol; (-)-CBD; GWP42003-P; CBD; 19GBJ60SN5; QHMBSVQNZZTUGM-ZWKOTPCHSA-N

Indication

Disease Entry	ICD 11	Status	REF
Dravet syndrome	8A61.11	Approved	[1]
LennoxGastaut syndrome	8A62.1	Approved	[1]
Infantile spasm	8A62.0	Phase 3	[2]
Epilepsy	8A60-8A68	Phase 2	[2]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 1:
  Molecular Weight (mw); 314.5
  Topological Polar Surface Area (xlogp); 6.5
  Rotatable Bond Count (rotbonds); 6
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 2
• ADMET Property:
  Clearance: The drug present in the plasma can be removed from the body at the rate of 13.55 mL/min/kg [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 1.44 hours (CBD component of sublingual Sativex), and 1.81 hours (buccal Sativex) [3]
  Metabolism: The drug is metabolized via the liver [4]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 6.69 L/kg [3]
• Chemical Identifiers:
  Formula: C21H30O2
  IUPAC Name: 2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
  Canonical SMILES: CCCCCC1=CC(=C(C(=C1)O)[C@@H]2C=C(CC[C@H]2C(=C)C)C)O
  InChI: InChI=1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t17-,18+/m0/s1
  InChIKey: QHMBSVQNZZTUGM-ZWKOTPCHSA-N
• Cross-matching ID:
  PubChem CID: 644019
  ChEBI ID: CHEBI:69478
  CAS Number: 13956-29-1
  DrugBank ID: DB09061
  TTD ID: D0O1UZ
  VARIDT ID: DR00249
  INTEDE ID: DR0265
  ACDINA ID: D00909

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cannabinoid receptor (CB)	TT94IAG	NOUNIPROTAC	Binder	[5]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[6]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[7]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[8]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[7]
Mephenytoin 4-hydroxylase (CYP2C19) Main DME	DEGTFWK	CP2CJ_HUMAN	Substrate	[7]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[8]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Cannabidiol (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Cannabidiol and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[58]
Tagraxofusp	DM9HQ5U	Moderate	Increased risk of hepatotoxicity by the combination of Cannabidiol and Tagraxofusp.	Acute myeloid leukaemia [2A60]	[59]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Cannabidiol caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[59]
Gilteritinib	DMWQ4MZ	Moderate	Increased risk of hepatotoxicity by the combination of Cannabidiol and Gilteritinib.	Acute myeloid leukaemia [2A60]	[59]
Inotersen	DMJ93CT	Moderate	Increased risk of hepatotoxicity by the combination of Cannabidiol and Inotersen.	Amyloidosis [5D00]	[59]
Troleandomycin	DMUZNIG	Minor	Decreased metabolism of Cannabidiol caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[59]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Cannabidiol and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[60]
LY2835219	DM93VBZ	Moderate	Increased risk of hepatotoxicity by the combination of Cannabidiol and LY2835219.	Breast cancer [2C60-2C6Y]	[59]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Cannabidiol caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[61]
Fenofibric acid	DMGO2MC	Moderate	Increased risk of hepatotoxicity by the combination of Cannabidiol and Fenofibric acid.	Cardiovascular disease [BA00-BE2Z]	[59]
Intedanib	DMSTA36	Moderate	Increased risk of hepatotoxicity by the combination of Cannabidiol and Intedanib.	Colorectal cancer [2B91]	[59]
MK-8228	DMOB58Q	Minor	Decreased metabolism of Cannabidiol caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[59]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Cannabidiol and Esketamine.	Depression [6A70-6A7Z]	[58]
Polatuzumab vedotin	DMF6Y0L	Moderate	Increased risk of hepatotoxicity by the combination of Cannabidiol and Polatuzumab vedotin.	Diffuse large B-cell lymphoma [2A81]	[59]
Stiripentol	DMMSDOY	Minor	Decreased metabolism of Cannabidiol caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[59]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Cannabidiol caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[62]
177Lu-DOTATATE	DMT8GVU	Moderate	Increased risk of hepatotoxicity by the combination of Cannabidiol and 177Lu-DOTATATE.	Hepatitis virus infection [1E50-1E51]	[59]
Cobicistat	DM6L4H2	Minor	Decreased metabolism of Cannabidiol caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[59]
Givosiran	DM5PFIJ	Moderate	Increased risk of hepatotoxicity by the combination of Cannabidiol and Givosiran.	Inborn porphyrin/heme metabolism error [5C58]	[59]
Berotralstat	DMWA2DZ	Minor	Decreased metabolism of Cannabidiol caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[59]
Ceritinib	DMB920Z	Moderate	Increased risk of hepatotoxicity by the combination of Cannabidiol and Ceritinib.	Lung cancer [2C25]	[59]
Alectinib	DMP1I6Y	Moderate	Increased risk of hepatotoxicity by the combination of Cannabidiol and Alectinib.	Lung cancer [2C25]	[59]
Pralsetinib	DMWU0I2	Moderate	Increased risk of hepatotoxicity by the combination of Cannabidiol and Pralsetinib.	Lung cancer [2C25]	[59]
Selpercatinib	DMZR15V	Moderate	Increased risk of hepatotoxicity by the combination of Cannabidiol and Selpercatinib.	Lung cancer [2C25]	[59]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Cannabidiol and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[59]
IPI-145	DMWA24P	Moderate	Increased risk of hepatotoxicity by the combination of Cannabidiol and IPI-145.	Mature B-cell leukaemia [2A82]	[59]
Arry-162	DM1P6FR	Moderate	Increased risk of hepatotoxicity by the combination of Cannabidiol and Arry-162.	Melanoma [2C30]	[59]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Cannabidiol and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[63]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Cannabidiol and Lasmiditan.	Migraine [8A80]	[64]
Siponimod	DM2R86O	Moderate	Increased risk of hepatotoxicity by the combination of Cannabidiol and Siponimod.	Multiple sclerosis [8A40]	[59]
Fedratinib	DM4ZBK6	Moderate	Increased risk of hepatotoxicity by the combination of Cannabidiol and Fedratinib.	Myeloproliferative neoplasm [2A20]	[59]
Entrectinib	DMMPTLH	Moderate	Increased risk of hepatotoxicity by the combination of Cannabidiol and Entrectinib.	Non-small cell lung cancer [2C25]	[59]
Sarilumab	DMOGNXY	Moderate	Increased risk of hepatotoxicity by the combination of Cannabidiol and Sarilumab.	Rheumatoid arthritis [FA20]	[59]
Voxelotor	DMCS6M5	Minor	Decreased metabolism of Cannabidiol caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[59]
Larotrectinib	DM26CQR	Moderate	Increased risk of hepatotoxicity by the combination of Cannabidiol and Larotrectinib.	Solid tumour/cancer [2A00-2F9Z]	[59]
LEE011	DMMX75K	Minor	Decreased metabolism of Cannabidiol caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[59]
Fostamatinib	DM6AUHV	Moderate	Increased risk of hepatotoxicity by the combination of Cannabidiol and Fostamatinib.	Thrombocytopenia [3B64]	[59]
Lenvatinib	DMB1IU4	Moderate	Increased risk of hepatotoxicity by the combination of Cannabidiol and Lenvatinib.	Thyroid cancer [2D10]	[59]
Elagolix	DMB2C0E	Moderate	Increased risk of hepatotoxicity by the combination of Cannabidiol and Elagolix.	Uterine fibroid [2E86]	[59]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Levomenthol	E00248	16666	Flavoring agent
Sucralose	E00370	71485	Flavoring agent
Ethanol	E00023	702	Antimicrobial preservative; Penetration agent; Solvent
Glycerin	E00026	753	Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Hydrogenated polyoxyl 40 castor oil	E00662	Not Available	Emulsifying agent; Solubilizing agent; Surfactant
Potassium sorbate	E00566	23676745	Antimicrobial preservative
Water	E00035	962	Solvent
Glyceryl oleate	E00618	Not Available	Other agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Cannabidiol 1.938 g/100 ml spray	1.938 g/100 ml	Spray	Oral
Cannabidiol 100 mg/ml solution	100 mg/ml	Solution	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [4] FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
• [5] (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol. 2002 Dec 5;456(1-3):99-106.
• [6] KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
• [7] Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015 Oct;12(4):699-730.
• [8] Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014 Feb;46(1):86-95.
• [9] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [10] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [11] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [12] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [13] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [14] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [15] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [16] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [17] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [18] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [19] Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
• [20] CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
• [21] Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
• [22] Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
• [23] Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
• [24] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [25] Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
• [26] Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
• [27] Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
• [28] Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
• [29] Drug Interactions Flockhart Table
• [30] Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
• [31] Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
• [32] Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
• [33] Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
• [34] Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
• [35] Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
• [36] Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
• [37] Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
• [38] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [39] Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
• [40] Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
• [41] New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
• [42] A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
• [43] A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
• [44] High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
• [45] Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
• [46] CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
• [47] Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
• [48] Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
• [49] Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
• [50] Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
• [51] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [52] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [53] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [54] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [55] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [56] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [57] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [58] Cerner Multum, Inc. "Australian Product Information.".
• [59] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [60] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [61] Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
• [62] Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
• [63] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [64] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.